Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
332
Stocks News & Analysis
stocks
Apple earnings: Strong performance overpowers headwinds, and we raise our FVE
stocks
Coles is winning the supermarket wars but is Woollies the better long-term opportunity?
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.50 | 24.00 | 0.26% |
| CAC 40 | 8,109.79 | 11.28 | -0.14% |
| DAX 40 | 24,132.41 | 174.11 | 0.73% |
| Dow JONES (US) | 47,358.68 | 204.19 | -0.43% |
| FTSE 100 | 9,701.37 | 15.88 | -0.16% |
| HKSE | 26,158.36 | 251.71 | 0.97% |
| NASDAQ | 23,855.36 | 130.40 | 0.55% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,556.30 | 7.98 | 0.06% |
| S&P 500 | 6,856.47 | 16.27 | 0.24% |
| S&P/ASX 200 | 8,894.80 | 36.20 | 0.41% |
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |